Discovers, develops, and produces pharmaceutical products. Focuses on creating regenerative medicine products and services. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 82% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 1.5× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 10% of them.
Analysts' average target sits 62% above today's price.
An investor who bought at the very peak is down 83% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $47.5M a year. A small number, but proof the product has real buyers.
There is $29.5M in the vault; even if every debt were paid off, $26.2M would remain.
A loss of $6.6M against $47.5M in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 7/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 10/100.
On our five-subject report card, BSEM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BSEM is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (10/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.